Tucatinib 'game changing' against HER2+ breast cancer, especially with brain metastases

(University of Colorado Anschutz Medical Campus) Phase III results at NEJM and SABCS: Adding tucatinib to standard of care treatment nearly tripled one-year progression-free survival.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news